Pharmacological assay model on the influence of the CYP2C9 gene mutation in anti-inflammatory drugs from saliva samples and their role in the prescription individualizatio
Not Applicable
Recruiting
- Conditions
- Investigation of cytochrome P450 polymorphisms, especially CYP2C9, and their role in the metabolism of non-steroidal anti-inflammatory drugs (NSAIDs).G05.365
- Registration Number
- RBR-38jcm9
- Lead Sponsor
- Faculdade de Odontologia de Bauru
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- Not specified
Inclusion Criteria
Good general health condition; absence of infection and inflammation; absence of systemic diseases; do not use any medicine that may alter the perception of pain or antidepressant, diuretic or anticoagulant medicines.
Exclusion Criteria
Patients with systemic diseases; patients with inflammation or infection; patients with a history of gastrointestinal bleeding or ulcerations; patients with cardiovascular, renal or liver disease; patients taking antidepressant, diuretic or anticoagulant medications; patients with a history of allergy to any other NSAIDs; pregnant and lactating women.
Study & Design
- Study Type
- Intervention
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Slower metabolization of non-steroidal anti-inflammatory drugs administered to individuals who have polymorphisms in the CYP2C9 gene compared to individuals without polymorphisms in CYP2C9. Metabolization will be assessed using mass spectrometry (LC MS/MS). Metabolization will be considered slower if it presents a statistical difference compared to the results of individuals without the polymorphism.
- Secondary Outcome Measures
Name Time Method Correlate the slower metabolization of individuals with polymorphisms in the CYP2C9 gene and less effective action of NSAIDs in terms of controlling inflammatory signals. Analysis of mass spectrometer data (LC MS / MS) and relevant clinical signs and symptoms, observed or reported. Outcome will be obtained by comparing the two groups and statistically relevant results.;Greater involvement of adverse effects with continuous use of NSAIDs (due to slower metabolism) in individuals with the polymorphic genotype of the CYP2C9 gene compared to those with wild genotype. Analysis of mass spectrometer data (LC MS / MS) and relevant clinical signs and symptoms, observed or reported. Outcome will be obtained by comparing the two groups and statistically relevant results.